Sanofi Licenses Possible Renagel/Renvela Successor From Ardelyx
This article was originally published in The Pink Sheet Daily
Executive Summary
The French pharma paid an undisclosed amount for rights to a preclinical phosphate transport program, one of several non-absorbable drugs that act locally within the gut. The deal comes as market-leading Renagel and Renvela face imminent generic competition.